InnoCore specializes in formulation, process development and manufacturing of long acting and minimally invasive injectable drug delivery products. We are a target-driven and cost-efficient organization committed to delivering products and services that offer added value to our partners and improve the quality of life of patients. Flexibility, compliance with the highest international quality standards and a true belief in the value of collaborative partnerships are the key elements of the InnoCore approach. InnoCore is a privately owned company and is based in The Netherlands.
Mission
Science delivering tomorrow's medicine
InnoCore is dedicated to develop minimally invasive and long-acting injectable polymer based depot formulation products for precise delivery of small molecules, peptides and protein therapeutics as to contribute to enhanced patient care.
History
Robert Hof (CEO) joined InnoCore
Succesfully developed semi-automated method for high throughput in-vitro release testing
More than 20 product development projects ongoing
Awarded by the Bill and Melissa Gates Foundation to develop a long-acting injectable contraceptive implant
Gates Foundation supported consortium on microneedle contraceptive
InnoCore renewed the GMP certificate and converted the laboratory authorization to a manufacturer’s authorization for physical/chemical testing of investigational medicines
InnoCore is offering InGell Technologies as a service
Winnter Enterpreneurs Award Groningen
InnoCore signs an Exclusive License with Allergan on Ophthalmology.
CE Mark for SynBiosys containing product with Orbus Neich.
InnoCore established a License in the field of device coatings with its US partner Surmodics Inc.
Foundation of InnoCore
